BIOTECHNOLOGY VALUE FUND II LP
CIK 1102444 · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.51B
Companies
20
Total Filings
46
Lifetime Open-Market Net
-$1.15B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 1,671,048 | $106.16 | $177.40M | -$1.43B | 4 | 2026-06-26 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 62,383 | $15.70 | $979.4K | $0 | 1 | 2025-06-17 | |
| MLTX | Director | 10,235,089 | $18.71 | $191.50M | $0 | 1 | 2025-06-09 |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,792,157 | $2.65 | $10.05M | $28.21M | 1 | 2023-11-03 | |
| RAIN | 1,479,460 | $1.32 | $1.95M | $21.20M | 3 | 2021-09-23 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 4,336,875 | $38.00 | $164.80M | $33.14M | 2 | 2020-10-08 | |
| XOMA | 10%+ Owner | 1,948,819 | $40.17 | $78.28M | $21.66M | 6 | 2020-09-01 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 3,927 | $13.60 | $53.4K | -$1.57M | 1 | 2019-09-10 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 6,372,596 | $0.04 | $284.9K | $20.07M | 2 | 2018-11-21 |
| SNDX | 85,038 | $19.63 | $1.67M | $0 | 1 | 2018-06-20 | |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 1,898,293 | — | — | $3.08M | 4 | 2015-02-09 | |
| CCXI | 485,412 | $14.52 | $7.05M | $11.62M | 1 | 2013-09-13 | |
| NBIX | 756,600 | $182.83 | $138.33M | $2.48M | 1 | 2011-10-12 | |
| CAPS | 952 | $0.25 | $236 | $1.55M | 2 | 2011-08-22 | |
| Celera CORP (CRA) Delisted | 31,520,834 | — | — | $155.25M | 4 | 2011-05-10 | |
| AVIGEN INC \DE (AVGN) Delisted | 15,674,378 | — | — | -$5.6K | 1 | 2009-11-20 | |
| RPRX | 2,145,776 | $59.97 | $128.68M | -$3.60M | 1 | 2009-09-24 | |
| CRIS | 4,097 | $4.83 | $19.8K | -$17.08M | 1 | 2009-04-29 | |
| LGND | 10%+ Owner | 2,663,034 | $296.28 | $789.00M | $5.66M | 5 | 2009-01-27 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 8,135,099 | — | — | $773.0K | 1 | 2008-11-12 |
Recent Filings · Page 3 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-21 | XOMA | Buy (P) | +505,771 | $7.17M | EDGAR |
| 2018-11-19 | XOMA | Buy (P) | +223,930 | $3.02M | EDGAR |
| 2018-06-20 | SNDX | Other (J) | −14,000,000 | $0 | EDGAR |
| 2016-12-20 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +4,584,447 | $5.99M | EDGAR |
| 2015-02-09 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Other (J) | −20,000,000 | $0 | EDGAR |
| 2014-07-16 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Other (J) | −2,771,190 | -$8.98M | EDGAR |
| 2013-11-05 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Buy (P) | +645,000 | $1.15M | EDGAR |
| 2013-09-13 | CCXI | Buy (P) | +1,953,810 | $11.62M | EDGAR |
| 2013-06-07 | Cascadian Therapeutics, Inc. (ONTY) Delisted | Buy (P) | +1,072,335 | $1.94M | EDGAR |
| 2011-10-12 | NBIX | Buy (P) | +443,400 | $2.48M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.